5 application of hpv vaccines final 31-05-10

8/12/2019 5 Application of HPV Vaccines FINAL 31-05-10

1/25

UICC HPV and Cervical Cancer CurriculumChapter 5. Application of HPV vaccines

Prof. Suzanne Garland MD

UICC

HPV and

CERVICALCANCERCURRICULUM


2/25



Slide

01 Chapter 5.

Application of HPV vaccines

Prof. Suzanne Garland MDDirector of Microbiological Research

Director of Clinical Microbiology and Infectious DiseasesThe Royal Women's Hospital

Melbourne, Australia


3/25



Slide

02Selection of the right age group

for vaccination

Genital HPV infections are common sexuallytransmitted infections

- Readily transmissible: within few months of start of sexual activity

- Cumulative lifetime risk of infection = 50-80%

- Cumulative lifetime exposure to HPV 16 and/or HPV 18 20%1

Natural history of HPV- Most HPV infections are transient: the majority of young women

clear HPV infection within 1-2 years 2

HPV type prevalence

- HPV prevalence among different populations of women range

from 2-44%, with worldwide overall prevalence of 10.4%- Age dependent

- Different profiles in different countries 3

1 Baseman J et al. Clin Virol 2005;32:16-24.2 Sankaranarayanan R et al. Vaccine 2008; 26: Suppl 12:M43-52.3 de Sanjos S et al. Lancet Inf Dis 2007;7:7 453-459.


4/25



Slide

03Selection of the right age group

for vaccination

Antibody responses in known age groups Antibody responses have been used as a surrogate to

bridge efficacy against cervical and/or vaginal disease in: 1-3

- Young women

- Pre-adolescence

- Mature women

Basis for registration 4

1 Munoz N et al. Lancet 2009;373:1949-57.2 Block SL et al. Pediatrics 2006;118(5):2135-45.3 Pedersen C et al. J Adolesc Health 2007;40(6):564-71.4 Skinner SR et al. Med J Aust 2008;188(4):238-242.


5/25



Slide

04

Efficacy against HPV vaccine-related disease correlateswith the presence of serum antibodies 1-4

Recipients show rapid development of high titre (many

fold greater than natural infection)

Currently no identified correlate of protection

Immune responses are age-dependent 5,6

Selection of the right age group

for vaccination

1 Harper et al Lancet 2006:1247-55.2 Villa LL et al Brit J of Cancer 2006;95(11):1459-66.3 Villa LL et al. Vaccine 2006;24:4931-39.4 Harper D et al. Gynec Oncol 2008;109(1):158.5 Block SL et al. Pediatrics 2006;118(5):2135-45.6 Pedersen C et al. J Adolesc Health 2007;40(6):564-71


6/25



Slide

05

Dependent on age of sexual debut (culture-dependent):

age of sexual debut is decreasing over time in some

countries, but this trend is less pronounced and less

widespread than sometimes supposed 1

Prophylactic HPV vaccines are licensed for the ages of 9

to 12 years in many countries


for vaccination

1 Wellings K et al. Lancet 2006; 368:1706-28


7/25



Slide

06

Needs to be practical for vaccine delivery

- School-based programmes

- Adolescent health programme focus

- Practitioner-based programme

Collaborate with already existing childhood extendedimmunisation programmes (EPI)

- Maximise implementation using already established

vaccination infrastructure


for vaccination


8/25



Slide

07 HPV vaccination in boys?

Clinical trials in boys

- Immunogenicity has been shown with both vaccines 13,14

- Preliminary results are available showing protection from

infection and external genital warts for the quadrivalent

vaccine 15

Cost-effectiveness?

Would allow destigmatisation of females

Herd immunity: effect on females with lower uptake of

vaccine

13 Reisinger KS et al. Pediatr Infect Dis J. 2007 Mar;26(3):201-9.14 Petj T et al. J Adolesc Health. 2009 Jan;44(1):33-40.15 Palefsky J. Eurogin February 2010.


9/25



Slide

08Does prophylactic vaccination replace

cervical screening?

Efficacy following three doses of vaccine for those nave

to vaccine-related HPVs is nearly 100% 16-18

About 30% of cancers are caused by non-vaccine related-

HPVs

- Immunity largely type-specific

Some cross-protection to HPV types phylogenetically

related to HPV 16 and HPV 18

16 Garland SM et al. NEJM 2007;356:1928-1943.17 FUTURE II SG. NEJM 2007;356:1915-1927.18 Paavonen J et al. Lancet 2007;369:2161-2170.


10/25



Slide

09

Some form of screening is still required

Challenges with an implemented vaccine programme: 19

- Screening sensitivity and positive predictive value for

high-grade lesions will be reduced with vaccination

- Reduced future cancer burden through primary

prevention, cervical screening programmes will be much

less cost-effective

- Vaccinees may be unclear as to the need for Pap test

Does prophylactic vaccination replace

cervical screening?

19 Cuzick et al. Vaccine 26S; 2008: K29-41.


11/25



Slide

10Vaccinating sexually active women: is

prior HPV DNA testing mandatory ?

From a public health point of view, this is not

recommended

- A negative test does not tell you whether a woman has

previously been infected

- A positive test could be a newly acquired infection or a

persistent infection- More likely negative if transient infection


12/25



Slide

11Vaccinating sexually active women:

measure antibodies before vaccinating?

HPV antibodies

- A poor marker of past or present infection, ~ 60% of

those HPV DNA-positive have a measurable serological

response 20

- Serological responses are slow (take up to 12-18

months post-infection)- No reliable diagnostic assays exist

- Assays need to be standardised 21

20 Carter JJ et al J Infect Dis 2000, 181,1911-1919.21 Pagliusi SR, Garland SM. Molecular Markers 2007;9(32):1-14.


13/25



Slide

12Opportunities for HPV vaccination in

low-resource countries

GAVI-subsidized childhood vaccination programmes for

72 countries (late 2008/early 2009)

Need for similar GAVI endorsement of HPV vaccines

Reduced pricing of HPV vaccines for poorer countries

- Accelerated Development and Introduction Plans

(ADIPs)

- Mechanisms such as the Advanced Market Commitment

(AMC)


14/25



Slide

13Are three injections mandatory for

efficient protection?

Very limited data on prevention of infection or disease with

two-dose schedule

- High compliance of study participants to three-dose

schedule

Given the nature of the vaccine, likely that three doses will

be required as with HBV Studies to evaluate modifications to current vaccine

schemes are ongoing


15/25



Slide

14Vaccine effectiveness: need for

ongoing surveillance

HPV genotyping

- Prevalence: normal cytology, cervical dysplasia/cancer

- Vaccine-related type prevalence change?

- Protection against phylogenetically related non-vaccine

types?

- Replacement of vaccine HPV types?

- HPV serosurveillance

Genital wart surveillance (females and males)


16/25



Slide

15Putting all the pieces together: HPV

vaccination programme in Australia

Australia was the first country to implement a national

vaccine programme funded by the government

Vaccination in both girls and boys

Included a catch-up programme in women

Cervical screening programme already in progress


17/25



Slide

16The Australian National HPV

Vaccination Programme (1)

November 2006

- Commonwealth Minister for Health announced funding

for HPV vaccine (Gardasil)

April 1st 2007

- Added to National Immunisation Programme on an

ongoing basis for 12-13 year-old girls via schools

July 2007 December 2009

- Two-year catch-up programme for 12-26 year-old

females


18/25



Slide



Three components:

Ongoing school-based programme

1. Girls aged 12-13 years (first year of high school)

Two-year catch-up programme to 2009

2. Girls/adolescent females aged 12-18 years

- School-based +/- community-based mop up

3. Young women aged 18-26 years

- General practitioners and other community-based

services


19/25



Slide



Vaccination coverage (by the end of May 2009)

- 5 million doses of the vaccine distributed (~80%) first

years cohort

- ~60% coverage of the eligible population in the catch-up

group of young females

- Rural areas: 70% of target age groups received firstdose


20/25

UICC HPV and Cervical Cancer CurriculumChapter 5. Application of HPV vaccinesProf. Suzanne Garland MD

Slide

19Community-based programme:

18-26 year-olds

Difficult demographic to ensure completion of 3-dose

vaccine schedule

Implementation strategy:

- Motivate and empower young women to protect

themselves

- Support GP clinics to run pro-active vaccinationcampaign

- High-profile advertising and public relations campaign


21/25


Slide

20National HPV Vaccination Register

National HPV Vaccination Register launched by the

Australian Government (VCCR)

- Collect information on vaccination programme

- Evaluate impact of vaccination on cervical abnormality

and cancer rates by matching with Pap test registers

Document doses of HPV vaccine and dates administered

- Assess age-specific coverage achieved

- Contact if booster doses required

- Link to Pap Screen registers

- Evaluate the impact of the vaccine on cervical cancer

Providers must report vaccination in 12-18 year age group

- Victorian councils using Immunisation Provider System

(ImPS) to collect data


22/25


Slide

21Lessons learned, future directions

and challenges

Opportunities to link the National HPV vaccine Register

with:

- Cervical cytology screening registers

- HPV genotype prevalence surveillance pre- and post-

vaccine implementation

- Ultimately cancer registers for ongoing surveillance

Communication, feedback, goodwill, etc.

Vaccine effectiveness

Evaluation of cervical screening practices


23/25


Slide

22Lessons learned, future directions

and challenges

Approaches for implementation of HPV vaccination

programmes are different between countries

Australia, UK, Canada: successful public-sector HPV

vaccination programmes primarily based on school-based

provision, and largely covered by public sector funds for

all age-eligible female adolescents 1-3

Resulted in relatively high rates of HPV vaccination

coverage: e.g. Australia coverage up to 80% 2,3

1 Shefer et al. Vaccine 2008;26(Suppl 10):K68-752 Brotherton JM et al. Commun Dis Intell 2008;32:457-613 Garland SM et al. Vaccine 2008;26(Suppl 12):M80-8


24/25


Slide

23Challenges and future directions

Largely vaccinated cohort of Australian women

Review and re-engineer National Cervical Screening

Programme (NCSP) introduced in 1991

NSCP currently recommends cervical cytology screening

for all women who have ever had sex

- Start at 18-20 years or 1-2 years after start of sexualintercourse, which ever is later

- Repeat Pap smear every 2 years

- Screening ends at age 70 if 2 normal Pap smears within

last 5 years


25/25

UICC HPV and Cervical Cancer CurriculumChapter 5. Application of HPV vaccinesP f S G l d MD

Slide

24

Thank you

This presentation is available atwww.uicc.org/cervicalcancercurriculum

5 application of hpv vaccines final 31-05-10

Documents